Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs

Shanghai, China, September 26,2021– Asieris Pharmaceuticals today announced that it has been named as one of the Top 30 Chinese Innovative Enterprises in Small Molecule Drugs at the conference held by Menet in Suzhou. As a global innovative pharmaceutical company specializing in genitourinary tumors and other major diseases in China, Asieris entered the Top 30 list and was awarded at the ceremony.

The list is designed to reflect the capabilities of biopharma companies to drive innovation, and it selects the top 100 based on 11 indicators in four dimensions including R&D investment, achievements, intellectual property rights and transformation. The evaluation criteria are in line with the system to assess corporate innovation abilities set by the Ministry of Science and Technology in China.

This award also proves the company’s strength to advance innovation in the specialized fields. After more than 10 years of fast development, Asieris has built three core technology platforms and is currently carrying out research and development and registration of nine products. Among them, the three studies of two products are in Phase III/pivotal clinical trials.

Asieris is committed to the mission to improve human health and help people live a more dignified life. It will continue to strengthen its in-house research and development capabilities, actively explore the integrated diagnosis and treatment model, and provide overall solutions for patients.

About Asieris

Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.

The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.

Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.